Cargando…
Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies
Elevated plasma level of soluble endothelial protein C receptor (sEPCR) may be an indicator of thrombotic risk. The present study aims to correlate leukemia-associated hypercoagulability to high level plasma sEPCR and proposes its measurement in routine clinical practice. EPCR expressions in leukemi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544449/ https://www.ncbi.nlm.nih.gov/pubmed/23342274 http://dx.doi.org/10.1002/cam4.11 |
_version_ | 1782255787512430592 |
---|---|
author | Ducros, Elodie Mirshahi, Shah Soltan Faussat, Anne-Marie Mirshahi, Pezhman Dimicoli, Sophie Tang, Ruoping Pardo, Julia Ibrahim, Jdid Marie, Jean-Pierre Therwath, Amu Soria, Jeannette Mirshahi, Massoud |
author_facet | Ducros, Elodie Mirshahi, Shah Soltan Faussat, Anne-Marie Mirshahi, Pezhman Dimicoli, Sophie Tang, Ruoping Pardo, Julia Ibrahim, Jdid Marie, Jean-Pierre Therwath, Amu Soria, Jeannette Mirshahi, Massoud |
author_sort | Ducros, Elodie |
collection | PubMed |
description | Elevated plasma level of soluble endothelial protein C receptor (sEPCR) may be an indicator of thrombotic risk. The present study aims to correlate leukemia-associated hypercoagulability to high level plasma sEPCR and proposes its measurement in routine clinical practice. EPCR expressions in leukemic cell lines were determined by flow cytometry, immunocytochemistry, and reverse transcription polymerase chain reaction (RT-PCR). EPCR gene sequence of a candidate cell line HL-60 was also determined. Plasma samples (n = 76) and bone marrow aspirates (n = 72) from 148 patients with hematologic malignancies and 101 healthy volunteers were analyzed by enzyme-linked immunosorbent assay (ELISA) via a retrospective study for sEPCR and D-dimer. All leukemic cell lines were found to express EPCR. Also, HL-60 EPCR gene sequence showed extensive similarities with the endothelial reference gene. All single nucleotide polymorphisms (SNPs) originally described and some new SNPs were revealed in the promoter and intronic regions. Among these patients 67% had plasma sEPCR level higher than the controls (100 ± 28 ng/mL), wherein 16.3% patients had experienced a previous thrombotic event. These patients were divided into: group-1 (n = 45) with amount of plasmatic sEPCR below 100 ng/mL, group-2 (n = 45) where the concentration of sEPCR was between 100 and 200, and group-3 (n = 20) higher than 200 ng/mL. The numbers of thrombotic incidence recorded in each group were four, six, and eight, respectively. These results reveal that EPCR is expressed not only by a wide range of human malignant hematological cells but also the detection of plasma sEPCR levels provides a powerful insight into thrombotic risk assessment in cancer patients, especially when it surpasses 200 ng/mL. |
format | Online Article Text |
id | pubmed-3544449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-35444492013-01-22 Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies Ducros, Elodie Mirshahi, Shah Soltan Faussat, Anne-Marie Mirshahi, Pezhman Dimicoli, Sophie Tang, Ruoping Pardo, Julia Ibrahim, Jdid Marie, Jean-Pierre Therwath, Amu Soria, Jeannette Mirshahi, Massoud Cancer Med Cancer Prevention Elevated plasma level of soluble endothelial protein C receptor (sEPCR) may be an indicator of thrombotic risk. The present study aims to correlate leukemia-associated hypercoagulability to high level plasma sEPCR and proposes its measurement in routine clinical practice. EPCR expressions in leukemic cell lines were determined by flow cytometry, immunocytochemistry, and reverse transcription polymerase chain reaction (RT-PCR). EPCR gene sequence of a candidate cell line HL-60 was also determined. Plasma samples (n = 76) and bone marrow aspirates (n = 72) from 148 patients with hematologic malignancies and 101 healthy volunteers were analyzed by enzyme-linked immunosorbent assay (ELISA) via a retrospective study for sEPCR and D-dimer. All leukemic cell lines were found to express EPCR. Also, HL-60 EPCR gene sequence showed extensive similarities with the endothelial reference gene. All single nucleotide polymorphisms (SNPs) originally described and some new SNPs were revealed in the promoter and intronic regions. Among these patients 67% had plasma sEPCR level higher than the controls (100 ± 28 ng/mL), wherein 16.3% patients had experienced a previous thrombotic event. These patients were divided into: group-1 (n = 45) with amount of plasmatic sEPCR below 100 ng/mL, group-2 (n = 45) where the concentration of sEPCR was between 100 and 200, and group-3 (n = 20) higher than 200 ng/mL. The numbers of thrombotic incidence recorded in each group were four, six, and eight, respectively. These results reveal that EPCR is expressed not only by a wide range of human malignant hematological cells but also the detection of plasma sEPCR levels provides a powerful insight into thrombotic risk assessment in cancer patients, especially when it surpasses 200 ng/mL. Blackwell Publishing Ltd 2012-10 2012-07-23 /pmc/articles/PMC3544449/ /pubmed/23342274 http://dx.doi.org/10.1002/cam4.11 Text en © 2012 The Authors. Published by Blackwell Publishing Ltd. http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Cancer Prevention Ducros, Elodie Mirshahi, Shah Soltan Faussat, Anne-Marie Mirshahi, Pezhman Dimicoli, Sophie Tang, Ruoping Pardo, Julia Ibrahim, Jdid Marie, Jean-Pierre Therwath, Amu Soria, Jeannette Mirshahi, Massoud Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies |
title | Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies |
title_full | Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies |
title_fullStr | Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies |
title_full_unstemmed | Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies |
title_short | Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies |
title_sort | soluble endothelial protein c receptor (sepcr) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies |
topic | Cancer Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544449/ https://www.ncbi.nlm.nih.gov/pubmed/23342274 http://dx.doi.org/10.1002/cam4.11 |
work_keys_str_mv | AT ducroselodie solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies AT mirshahishahsoltan solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies AT faussatannemarie solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies AT mirshahipezhman solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies AT dimicolisophie solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies AT tangruoping solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies AT pardojulia solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies AT ibrahimjdid solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies AT mariejeanpierre solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies AT therwathamu solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies AT soriajeannette solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies AT mirshahimassoud solubleendothelialproteincreceptorsepcrislikelyabiomarkerofcancerassociatedhypercoagulabilityinhumanhematologicmalignancies |